Annals of thoracic surgery short reports最新文献

英文中文

Lung Cancer Screening in Head and Neck Cancer: An Opportunity to Increase Screening in Eligible Candidatess 头颈癌的肺癌筛查：增加合格候选人筛查的机会

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-07-30 DOI: 10.1016/j.atssr.2025.07.006

Julia Riccardi MD , Nina D. Ham BA , Nicole I. Farber MD , Lisa M. Brown MD, MAS , Marianne Abouyared MD , Mara B. Antonoff MD

Background

Lung cancer screening is as an effective strategy for early diagnosis in high-risk patients, with proven impact on decreasing mortality. Individuals with malignancies of the head and neck have risk factors similar to those with lung cancer, with the most notable being a shared association with current or previous smoking. We evaluated the prevalence of lung cancer screening candidacy and implementation among head and neck cancer clinic patients.

Methods

Anonymous surveys were collected from patients who presented to the head and neck cancer clinic at a single, tertiary-care center from May 2024 to August 2024. Individuals were queried regarding their candidacy for and experiences with lung cancer screening. Descriptive analyses were performed.

Results

A total of 202 patients were surveyed, with median age of 66 (interquartile range, 15) years. Within this cohort, 77 (38.0%) previously smoked and 15 (7.4%) currently smoked. Among all respondents, 23 (11.4%) met 2021 United States Preventative Service Taskforce criteria for lung cancer screening. Most of the patients (16 [69.6%]) who met criteria had never been offered screening. Seven patients (30.4%) who were eligible for lung cancer screening were previously offered screening and completed it. Of the 25 patients who were screened in the entire cohort, 5 (20%) were diagnosed with lung cancer.

Conclusions

A substantial proportion of head and neck cancer patients are eligible for lung cancer screening. The low levels of screening highlighted in this shared patient population serve as an opportunity for quality improvement, especially given the high frequency of cancer diagnoses among those who received screening.

背景肺癌筛查是高风险患者早期诊断的有效策略，已被证明对降低死亡率有影响。头颈部恶性肿瘤患者的风险因素与肺癌患者相似，最值得注意的是与当前或以前吸烟有共同的关联。我们评估了头颈癌临床患者肺癌筛查的候选性和实施情况。方法对2024年5月至2024年8月在单一三级保健中心头颈癌门诊就诊的患者进行匿名调查。个人被问及他们的候选资格和肺癌筛查的经验。进行描述性分析。结果共调查202例患者，中位年龄66岁（四分位数间距15岁）。在该队列中，77人（38.0%）以前吸烟，15人（7.4%）目前吸烟。在所有受访者中，23人（11.4%）符合2021年美国预防服务工作组肺癌筛查标准。大多数符合标准的患者（16例[69.6%]）从未接受过筛查。7名符合肺癌筛查条件的患者（30.4%）先前接受了筛查并完成了筛查。在整个队列中接受筛查的25名患者中，有5名（20%）被诊断患有肺癌。结论有相当比例的头颈癌患者适合肺癌筛查。在这一共有的患者群体中，筛查水平较低，这为提高质量提供了机会，特别是考虑到接受筛查的患者中癌症诊断的频率很高。

{"title":"Lung Cancer Screening in Head and Neck Cancer: An Opportunity to Increase Screening in Eligible Candidatess","authors":"Julia Riccardi MD , Nina D. Ham BA , Nicole I. Farber MD , Lisa M. Brown MD, MAS , Marianne Abouyared MD , Mara B. Antonoff MD","doi":"10.1016/j.atssr.2025.07.006","DOIUrl":"10.1016/j.atssr.2025.07.006","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer screening is as an effective strategy for early diagnosis in high-risk patients, with proven impact on decreasing mortality. Individuals with malignancies of the head and neck have risk factors similar to those with lung cancer, with the most notable being a shared association with current or previous smoking. We evaluated the prevalence of lung cancer screening candidacy and implementation among head and neck cancer clinic patients.</div></div><div><h3>Methods</h3><div>Anonymous surveys were collected from patients who presented to the head and neck cancer clinic at a single, tertiary-care center from May 2024 to August 2024. Individuals were queried regarding their candidacy for and experiences with lung cancer screening. Descriptive analyses were performed.</div></div><div><h3>Results</h3><div>A total of 202 patients were surveyed, with median age of 66 (interquartile range, 15) years. Within this cohort, 77 (38.0%) previously smoked and 15 (7.4%) currently smoked. Among all respondents, 23 (11.4%) met 2021 United States Preventative Service Taskforce criteria for lung cancer screening. Most of the patients (16 [69.6%]) who met criteria had never been offered screening. Seven patients (30.4%) who were eligible for lung cancer screening were previously offered screening and completed it. Of the 25 patients who were screened in the entire cohort, 5 (20%) were diagnosed with lung cancer.</div></div><div><h3>Conclusions</h3><div>A substantial proportion of head and neck cancer patients are eligible for lung cancer screening. The low levels of screening highlighted in this shared patient population serve as an opportunity for quality improvement, especially given the high frequency of cancer diagnoses among those who received screening.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"4 1","pages":"Pages 191-195"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147414545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Off-Pump Lung Transplantation: Key Surgical and Anesthetic Considerations 非泵肺移植：关键的手术和麻醉注意事项

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-08-19 DOI: 10.1016/j.atssr.2025.07.019

Yoshiya Toyoda MD , Akshay Chauhan MBBS , Gordon H. Morewood MD , Hiromu Kehara MD , Sean M. Baskin MD , Sriram Vijayapuri MBBS , Mikiko Senzai MD , Roh Yanagida MD , Kewal Krishan MBBS

This article presents an off-pump lung transplantation technique via bilateral anterior thoracotomy. It details anesthesia management, tailored ventilation, and surgical steps to maintain hemodynamic stability. Avoiding extracorporeal support, this approach minimizes bleeding and enhances recovery, offering a safe, efficient alternative to clamshell incision for experienced transplant teams.

本文介绍一种经双侧前开胸的无泵肺移植技术。它详细介绍了麻醉管理、量身定制的通气和维持血流动力学稳定的手术步骤。避免体外支持，这种方法最大限度地减少出血和促进恢复，为经验丰富的移植团队提供了翻盖切口的安全，有效的替代方案。

引用次数: 0

Surgery for Superior Sulcus Tumor, Partially Using a Robotic Approach, After Neoadjuvant Nivolumab With Platinum-Based Chemotherapy 上沟肿瘤的手术，部分使用机器人入路，在新辅助纳武单抗与铂基化疗后

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-10-03 DOI: 10.1016/j.atssr.2025.09.002

Hitoshi Igai MD, PhD , Akinobu Ida MD , Kazuki Numajiri MD , Kazuhito Nii MD, PhD , Mitsuhiro Kamiyoshihara MD, PhD

Superior sulcus tumors have traditionally been treated with concurrent chemoradiotherapy followed by surgical resection, although radiation-induced fibrosis complicates surgery. Recent studies suggest that neoadjuvant nivolumab combined with platinum-based chemotherapy improves prognosis while limiting perioperative complications. We successfully performed surgical resection of a superior sulcus tumor by using a hybrid approach: an L-shaped incision for chest wall resection and a robotic-assisted technique for left upper lobectomy and lymphadenectomy. The patient achieved a major pathologic response with an uneventful recovery. This case highlights the potential of neoadjuvant immunochemotherapy and robotic surgery in optimizing outcomes for superior sulcus tumor management.

传统上，上沟肿瘤的治疗是同步放化疗，然后手术切除，尽管放射诱导的纤维化使手术复杂化。最近的研究表明，新辅助纳武单抗联合铂基化疗可改善预后，同时限制围手术期并发症。我们成功地通过混合入路手术切除上沟肿瘤：l型切口胸壁切除术和机器人辅助技术左上肺叶切除术和淋巴结切除术。患者取得了主要的病理反应，并顺利康复。本病例强调了新辅助免疫化疗和机器人手术在优化上沟肿瘤治疗结果方面的潜力。

引用次数: 0

A 27-Year Comparative Analysis of Off-Pump and On-Pump Coronary Artery Bypass Grafting in Octogenarians 非体外循环与非体外循环冠状动脉旁路移植术在老年患者中的27年对比分析

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-07-31 DOI: 10.1016/j.atssr.2025.07.013

Maria Comanici MD , Anoosha Nair MD , Kabeer Umakumar FRCS(CTh) , Nandor Marczin PhD , Sunil K. Bhudia FRCS(CTh) , Shahzad G. Raja FRCS(CTh)

Background

Octogenarians are deemed a high-risk patient population with increased postoperative morbidity and mortality after conventional coronary artery bypass grafting with cardiopulmonary bypass. In such patients, reducing the invasiveness of the surgical procedure by avoiding cardiopulmonary bypass may improve outcomes. This study investigates the in-hospital outcomes, 30-day mortality, and long-term survival rates of off-pump coronary artery bypass (OPCAB) vs on-pump coronary artery bypass (ONCAB) in octogenarians and identifies significant preoperative predictors of long-term mortality.

Methods

This retrospective cohort study included octogenarian patients who underwent either OPCAB or ONCAB, between January 1996 and September 2023, at our institution. In-hospital outcomes, 30-day mortality, and long-term survival during 20 years were compared between the groups. Propensity score matching was used to adjust for baseline differences. Statistical analyses included univariate and multivariate Cox regression analyses and Kaplan-Meier survival estimates.

Results

Of 711 patients, 245 pairs were matched. Unmatched analysis showed that OPCAB had lower tracheostomy rates (1.5% vs 4.7%, P = .011) and lower 30-day mortality (3.7% vs 7.5%; P = .027). However, after matching, in-hospital outcomes and 30-day mortality were similar between groups. Long-term survival rates were also comparable. Age (hazard ratio [HR], 1.08; 95% CI, 1.00-1.17; P = .040), previous cardiac surgery (HR, 68.16; 95% CI, 7.88-589.69; P < .001), and left ventricular impairment (HR, 1.59; 95% CI, 1.22-2.08; P < .001) were significant predictors of long-term mortality.

Conclusions

OPCAB may reduce short-term mortality in octogenarians while providing comparable long-term survival to ONCAB. Surgical strategy should be individualized on the basis of preoperative risk profiles.

背景：在常规冠状动脉旁路移植术合并体外循环后，老年患者被认为是术后发病率和死亡率较高的高危患者群体。在这类患者中，通过避免体外循环来减少手术过程的侵入性可能会改善结果。本研究调查了80多岁老人非体外循环冠状动脉搭桥术（OPCAB）与非体外循环冠状动脉搭桥术（ONCAB）的住院结果、30天死亡率和长期生存率，并确定了长期死亡率的重要术前预测因素。方法本回顾性队列研究纳入1996年1月至2023年9月在我院接受OPCAB或ONCAB的80多岁患者。比较两组的住院结果、30天死亡率和20年的长期生存率。倾向评分匹配用于调整基线差异。统计分析包括单因素和多因素Cox回归分析和Kaplan-Meier生存估计。结果711例患者配对245对。非匹配分析显示，OPCAB的气管造口率较低（1.5% vs 4.7%, P = 0.011）， 30天死亡率较低（3.7% vs 7.5%, P = 0.027）。然而，经过匹配，两组之间的住院结果和30天死亡率相似。长期存活率也具有可比性。年龄（风险比[HR]， 1.08; 95% CI, 1.00-1.17; P = 0.040）、既往心脏手术（HR, 68.16; 95% CI, 7.88-589.69; P < 0.001）和左心室损伤（HR, 1.59; 95% CI, 1.22-2.08; P < 0.001）是长期死亡率的重要预测因素。结论sopcab可以降低80岁老人的短期死亡率，同时提供与ONCAB相当的长期生存。手术策略应在术前风险概况的基础上个性化。

{"title":"A 27-Year Comparative Analysis of Off-Pump and On-Pump Coronary Artery Bypass Grafting in Octogenarians","authors":"Maria Comanici MD , Anoosha Nair MD , Kabeer Umakumar FRCS(CTh) , Nandor Marczin PhD , Sunil K. Bhudia FRCS(CTh) , Shahzad G. Raja FRCS(CTh)","doi":"10.1016/j.atssr.2025.07.013","DOIUrl":"10.1016/j.atssr.2025.07.013","url":null,"abstract":"<div><h3>Background</h3><div>Octogenarians are deemed a high-risk patient population with increased postoperative morbidity and mortality after conventional coronary artery bypass grafting with cardiopulmonary bypass. In such patients, reducing the invasiveness of the surgical procedure by avoiding cardiopulmonary bypass may improve outcomes. This study investigates the in-hospital outcomes, 30-day mortality, and long-term survival rates of off-pump coronary artery bypass (OPCAB) vs on-pump coronary artery bypass (ONCAB) in octogenarians and identifies significant preoperative predictors of long-term mortality.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included octogenarian patients who underwent either OPCAB or ONCAB, between January 1996 and September 2023, at our institution. In-hospital outcomes, 30-day mortality, and long-term survival during 20 years were compared between the groups. Propensity score matching was used to adjust for baseline differences. Statistical analyses included univariate and multivariate Cox regression analyses and Kaplan-Meier survival estimates.</div></div><div><h3>Results</h3><div>Of 711 patients, 245 pairs were matched. Unmatched analysis showed that OPCAB had lower tracheostomy rates (1.5% vs 4.7%, <em>P</em> = .011) and lower 30-day mortality (3.7% vs 7.5%; <em>P</em> = .027). However, after matching, in-hospital outcomes and 30-day mortality were similar between groups. Long-term survival rates were also comparable. Age (hazard ratio [HR], 1.08; 95% CI, 1.00-1.17; <em>P</em> = .040), previous cardiac surgery (HR, 68.16; 95% CI, 7.88-589.69; <em>P</em> < .001), and left ventricular impairment (HR, 1.59; 95% CI, 1.22-2.08; <em>P</em> < .001) were significant predictors of long-term mortality.</div></div><div><h3>Conclusions</h3><div>OPCAB may reduce short-term mortality in octogenarians while providing comparable long-term survival to ONCAB. Surgical strategy should be individualized on the basis of preoperative risk profiles.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"4 1","pages":"Pages 38-42"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical Aortic Valve Outcomes With Transcatheter Aortic Valve Replacement Hospital Status 经导管主动脉瓣置换术的手术结果

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-07-30 DOI: 10.1016/j.atssr.2025.07.002

Maxwell C. Braasch MD, MPH , Fengxian Wang PhD , R.J. Waken PhD , Karen E. Joynt Maddox MD, MPH , Alexander A. Brescia MD, MSc , Tsuyoshi Kaneko MD

Background

Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are treatments of aortic stenosis. There remain hospitals that perform SAVR and not TAVR. The study objective was to compare SAVR outcomes at SAVR-only hospitals with those at SAVR/TAVR hospitals.

Methods

Medicare beneficiaries who underwent SAVR from January 2018 to June 2023 were analyzed. Logistic regression analyses were performed to determine whether 30-day and 1-year mortality of patients undergoing SAVR differed between SAVR-only and SAVR/TAVR hospitals from 2021 to 2023.

Results

A total of 98,003 SAVRs occurred from 2018 to 2023, including 94,170 performed at SAVR/TAVR hospitals. From 2021 to 2023, 30-day and 1-year mortality after SAVR was higher at SAVR-only hospitals than at SAVR/TAVR hospitals (7.3% vs 5% [P < .0001]; 14.1% vs 8.8% [P < .0001]). All SAVRs at SAVR-only hospitals had higher odds of both 30-day (odds ratio [OR], 1.68 [CI, 1.31-2.17]) and 1-year (OR, 1.77 [CI, 1.44-2.19]) mortality compared with SAVRs performed at SAVR/TAVR hospitals, whereas there was no difference in 30-day (OR, 1.22 [CI, 0.71-2.10]) or 1-year mortality (OR, 0.82 [CI, 0.58-1.19]) for isolated SAVRs.

Conclusions

Mortality after all SAVRs is higher at SAVR-only hospitals than at SAVR/TAVR hospitals, but not for isolated SAVR. Further research is needed to understand whether the Center of Excellence concept is the best avenue to improve SAVR mortality.

手术主动脉瓣置换术（SAVR）和经导管主动脉瓣置换术（TAVR）都是主动脉瓣狭窄的治疗方法。仍然有医院进行SAVR而不是TAVR。研究目的是比较SAVR医院的SAVR结果与SAVR/TAVR医院的SAVR结果。方法分析2018年1月至2023年6月接受SAVR的医疗保险受益人。进行Logistic回归分析，以确定2021年至2023年，接受SAVR治疗的患者30天和1年死亡率在单纯SAVR和SAVR/TAVR医院之间是否存在差异。结果2018 - 2023年共发生98,003例SAVR，其中在SAVR/TAVR医院发生94170例。从2021年到2023年，单纯SAVR医院的SAVR术后30天和1年死亡率高于SAVR/TAVR医院（7.3% vs 5% [P < .0001]; 14.1% vs 8.8% [P < .0001]）。与在SAVR/TAVR医院进行的SAVR相比，在仅SAVR医院进行的所有SAVR患者的30天死亡率（比值比[OR]， 1.68 [CI, 1.31-2.17]）和1年死亡率（比值比[OR]， 1.77 [CI, 1.44-2.19]）均高于在SAVR/TAVR医院进行的SAVR患者，而单独SAVR患者的30天死亡率（比值比[OR]， 1.22 [CI, 0.71-2.10]）和1年死亡率（比值比[OR]， 0.82 [CI, 0.58-1.19]）无差异。结论单纯SAVR医院的SAVR术后死亡率高于SAVR/TAVR医院，但孤立性SAVR的死亡率不高。需要进一步的研究来了解卓越中心的概念是否是改善SAVR死亡率的最佳途径。

{"title":"Surgical Aortic Valve Outcomes With Transcatheter Aortic Valve Replacement Hospital Status","authors":"Maxwell C. Braasch MD, MPH , Fengxian Wang PhD , R.J. Waken PhD , Karen E. Joynt Maddox MD, MPH , Alexander A. Brescia MD, MSc , Tsuyoshi Kaneko MD","doi":"10.1016/j.atssr.2025.07.002","DOIUrl":"10.1016/j.atssr.2025.07.002","url":null,"abstract":"<div><h3>Background</h3><div>Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are treatments of aortic stenosis. There remain hospitals that perform SAVR and not TAVR. The study objective was to compare SAVR outcomes at SAVR-only hospitals with those at SAVR/TAVR hospitals.</div></div><div><h3>Methods</h3><div>Medicare beneficiaries who underwent SAVR from January 2018 to June 2023 were analyzed. Logistic regression analyses were performed to determine whether 30-day and 1-year mortality of patients undergoing SAVR differed between SAVR-only and SAVR/TAVR hospitals from 2021 to 2023.</div></div><div><h3>Results</h3><div>A total of 98,003 SAVRs occurred from 2018 to 2023, including 94,170 performed at SAVR/TAVR hospitals. From 2021 to 2023, 30-day and 1-year mortality after SAVR was higher at SAVR-only hospitals than at SAVR/TAVR hospitals (7.3% vs 5% [<em>P</em> < .0001]; 14.1% vs 8.8% [<em>P</em> < .0001]). All SAVRs at SAVR-only hospitals had higher odds of both 30-day (odds ratio [OR], 1.68 [CI, 1.31-2.17]) and 1-year (OR, 1.77 [CI, 1.44-2.19]) mortality compared with SAVRs performed at SAVR/TAVR hospitals, whereas there was no difference in 30-day (OR, 1.22 [CI, 0.71-2.10]) or 1-year mortality (OR, 0.82 [CI, 0.58-1.19]) for isolated SAVRs.</div></div><div><h3>Conclusions</h3><div>Mortality after all SAVRs is higher at SAVR-only hospitals than at SAVR/TAVR hospitals, but not for isolated SAVR. Further research is needed to understand whether the Center of Excellence concept is the best avenue to improve SAVR mortality.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"4 1","pages":"Pages 87-93"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147414405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cavoatrial Partial Heart Transplant: Ex Vivo Feasibility of a Novel Fontan Conduit 心房部分心脏移植：一种新型Fontan导管的体外可行性

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-09-11 DOI: 10.1016/j.atssr.2025.08.017

Harma Khachig Turbendian MD , Shannon Egli MS , Herra Javed MD , Anshaal Furrukh MD , Simon Chung MS , Taufiek Konrad Rajab MD

Background

The Fontan circulation is the single common pathway for patients with single ventricle defects, but has adverse effects due to passive pulmonary blood flow. Pulsatile pulmonary blood flow may mitigate the adverse effects of Fontan circulation, but a subpulmonary assist device is yet to reach clinical use. We hypothesize that fresh right atrial homograft (cavoatrial partial heart transplant [CAPHT]) may be utilized as a pulsatile Fontan conduit with growth potential.

Methods

The surgical technique for CAPHT conduit procurement was demonstrated in a live porcine donor. The CAPHT conduit was connected to a cardiopulmonary bypass circuit utilizing different cannulation orientations for inflow and outflow. Electrical activity and transduced pressure were recorded.

Results

Freshly procured live porcine CAPHT conduits demonstrate pulsatility with extracorporeal perfusion. The conduits have a variable intrinsic rhythm but have the ability to be paced epicardially. With adequate volume loading, the average generated pulse pressure was 9.2 mm Hg. The CAPHT conduit maintains viability and pulsatility for at least 152 minutes while connected to extracorporeal perfusion.

Conclusions

Our preliminary investigations demonstrate the technique for CAPHT conduit procurement. We show that the right atrium and vena cava can maintain viability pulsatility independent of coronary blood flow in an ex vivo setting. Subsequent in vivo studies will aim to evaluate the viability, function, and feasibility of the CAPHT conduit as an alternative extracardiac Fontan conduit that can be used as a subpulmonary assist device with growth potential.

Fontan循环是单心室缺陷患者的唯一常见途径，但由于肺动脉血流被动，会产生不良反应。搏动性肺血流可能减轻Fontan循环的不良影响，但肺下辅助装置尚未达到临床应用。我们假设新鲜的同种右心房移植（腔房部分心脏移植[CAPHT]）可能被用作具有生长潜力的搏动方丹导管。方法用活体猪供体进行CAPHT导管获取的手术技术验证。CAPHT导管连接到体外循环回路，利用不同的插管方向进行流入和流出。记录电活动和感应压力。结果新鲜制备的活猪CAPHT导管在体外灌注下具有搏动性。导管具有可变的内在节律，但具有心外膜节律的能力。在容量负荷充足的情况下，平均产生的脉压为9.2 mm Hg。在连接体外灌注时，CAPHT导管可保持至少152分钟的活力和脉动性。结论初步研究表明，该技术可用于CAPHT导管的获取。我们表明，在离体情况下，右心房和腔静脉可以维持独立于冠状动脉血流的活力搏动。随后的体内研究旨在评估CAPHT导管作为具有生长潜力的肺下辅助装置的心外Fontan导管的可行性、功能和可行性。

{"title":"Cavoatrial Partial Heart Transplant: Ex Vivo Feasibility of a Novel Fontan Conduit","authors":"Harma Khachig Turbendian MD , Shannon Egli MS , Herra Javed MD , Anshaal Furrukh MD , Simon Chung MS , Taufiek Konrad Rajab MD","doi":"10.1016/j.atssr.2025.08.017","DOIUrl":"10.1016/j.atssr.2025.08.017","url":null,"abstract":"<div><h3>Background</h3><div>The Fontan circulation is the single common pathway for patients with single ventricle defects, but has adverse effects due to passive pulmonary blood flow. Pulsatile pulmonary blood flow may mitigate the adverse effects of Fontan circulation, but a subpulmonary assist device is yet to reach clinical use. We hypothesize that fresh right atrial homograft (cavoatrial partial heart transplant [CAPHT]) may be utilized as a pulsatile Fontan conduit with growth potential.</div></div><div><h3>Methods</h3><div>The surgical technique for CAPHT conduit procurement was demonstrated in a live porcine donor. The CAPHT conduit was connected to a cardiopulmonary bypass circuit utilizing different cannulation orientations for inflow and outflow. Electrical activity and transduced pressure were recorded.</div></div><div><h3>Results</h3><div>Freshly procured live porcine CAPHT conduits demonstrate pulsatility with extracorporeal perfusion. The conduits have a variable intrinsic rhythm but have the ability to be paced epicardially. With adequate volume loading, the average generated pulse pressure was 9.2 mm Hg. The CAPHT conduit maintains viability and pulsatility for at least 152 minutes while connected to extracorporeal perfusion.</div></div><div><h3>Conclusions</h3><div>Our preliminary investigations demonstrate the technique for CAPHT conduit procurement. We show that the right atrium and vena cava can maintain viability pulsatility independent of coronary blood flow in an ex vivo setting. Subsequent in vivo studies will aim to evaluate the viability, function, and feasibility of the CAPHT conduit as an alternative extracardiac Fontan conduit that can be used as a subpulmonary assist device with growth potential.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"4 1","pages":"Pages 148-152"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147414930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Port Robotic-Assisted Epicardial Lead Placement for Cardiac Resynchronization Therapy 心脏再同步化治疗的单端口机器人辅助心外膜导联置入

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-11-07 DOI: 10.1016/j.atssr.2025.09.039

Blaz Podgorsek MD , Philippe Tremblay MD, MS , Danny Ramzy MD, PhD

We present a case demonstrating the novel use of the da Vinci SP (single-port) robotic platform (Intuitive Surgical) in cardiac surgery. A 69-year-old man with ischemic cardiomyopathy and failed endovascular cardiac resynchronization therapy defibrillator lead placement underwent successful robotically assisted left ventricular epicardial lead implantation through a 4-cm minithoracotomy. The da Vinci SP system enhanced visualization and dexterity, thus allowing for precise lead placement with minimal invasiveness. The patient recovered uneventfully and remained stable at follow-up. This case highlights the feasibility and potential advantages of single-port robotic-assisted cardiac procedures in select patients.

我们提出了一个案例，展示了达芬奇SP（单端口）机器人平台（直觉外科）在心脏手术中的新应用。一名69岁的缺血性心肌病患者，血管内心脏再同步化治疗失败，通过4厘米的小开胸成功地进行了机器人辅助的左心室心外膜导联植入。达芬奇SP系统增强了可视化和灵活性，因此可以以最小的侵入性精确放置导联。患者恢复平稳，随访时病情稳定。本病例强调了单孔机器人辅助心脏手术在特定患者中的可行性和潜在优势。

引用次数: 0

Thoracic Duct-to-Azygous Vein Lymphovenous Anastomosis for Lymphatic Decompression: Initial Experience and Early Outcomes 胸导管-奇静脉-淋巴静脉吻合术用于淋巴减压：初步经验和早期结果

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-09-13 DOI: 10.1016/j.atssr.2025.08.020

Benjamin Smood MD, MS , Katsuhide Maeda MD, PhD , Rosa Hwang BS , Dalal Taha DO , Yoav Dori MD, PhD , Christopher Smith MD, PhD , Pablo Laje MD

Background

Thoracic duct obstruction can cause devastating lymphatic complications, and definitive treatments remain lacking. This investigation evaluated our initial experience and early outcomes using a surgically created thoracic duct-to-azygous vein lymphovenous anastomosis (TDA-LVA) to provide lymphatic decompression in critically ill neonates and infants with thoracic duct obstruction.

Methods

All children who underwent TDA-LVA creation at the Children’s Hospital of Philadelphia between December 2019 and January 2024 were retrospectively reviewed. Preoperative and postoperative clinical characteristics were compared among all patients. Primary end points of analysis included survival to discharge and at last follow-up.

Results

Eight children (median weight, 4.5 kg; interquartile range [IQR], 3.5-5.0 kg) underwent successful TDA-LVA creation. All procedures were tolerated very well. One patient (1 of 8 [12.5%]) required chest washout on postoperative day (POD) 7, and 1 TDA-LVA was unsuccessfully revised on POD 21. The median hospital length of stay after TDA-LVA creation was 138 days (IQR, 64-241 days). Overall, 6 of 8 patients (75.0%) survived to hospital discharge, all of which (6 of 6 [100.0%]) remained alive at a median follow-up of 165 days (IQR, 18-521 days) after discharge. Postoperative TDA-LVA patency was confirmed with conventional lymphangiography in 5 of 8 patients (62.5%), and up to POD 70.

Conclusions

A TDA-LVA can restore lymphatic fluid drainage into the systemic venous circulation and remain patent for >2 months in carefully selected patients with thoracic duct obstruction. Further investigations are needed to determine the long-term durability and potential impact on overall quality of life and survival in children with complex lymphatic disorders.

背景：胸导管梗阻可引起毁灭性的淋巴并发症，目前尚无明确的治疗方法。本研究评估了我们的初步经验和早期结果，使用手术创建的胸导管-奇静脉-淋巴静脉吻合术（TDA-LVA）为危重新生儿和胸导管阻塞的婴儿提供淋巴减压。方法回顾性分析2019年12月至2024年1月在费城儿童医院接受TDA-LVA手术的所有儿童。比较所有患者术前和术后的临床特征。主要分析终点包括生存至出院和最后随访。结果8例患儿（中位体重4.5 kg，四分位间距3.5 ~ 5.0 kg）成功完成TDA-LVA的创建。所有的手术都能很好地耐受。1例患者（8例中的1例[12.5%]）在术后第7天（POD）需要洗胸，1例患者在第21天（POD）修改TDA-LVA失败。TDA-LVA创建后的中位住院时间为138天（IQR， 64-241天）。总体而言，8例患者中有6例（75.0%）存活至出院，其中6例（100.0%）在出院后中位随访165天（IQR， 18-521天）仍存活。术后8例患者中有5例（62.5%）经常规淋巴管造影证实TDA-LVA通畅，POD达70。结论经筛选的胸导管梗阻患者经TDA-LVA可恢复淋巴液引流至全身静脉循环，并可保持通畅2个月。需要进一步的研究来确定复杂淋巴疾病儿童的长期持久性和对整体生活质量和生存的潜在影响。

{"title":"Thoracic Duct-to-Azygous Vein Lymphovenous Anastomosis for Lymphatic Decompression: Initial Experience and Early Outcomes","authors":"Benjamin Smood MD, MS , Katsuhide Maeda MD, PhD , Rosa Hwang BS , Dalal Taha DO , Yoav Dori MD, PhD , Christopher Smith MD, PhD , Pablo Laje MD","doi":"10.1016/j.atssr.2025.08.020","DOIUrl":"10.1016/j.atssr.2025.08.020","url":null,"abstract":"<div><h3>Background</h3><div>Thoracic duct obstruction can cause devastating lymphatic complications, and definitive treatments remain lacking. This investigation evaluated our initial experience and early outcomes using a surgically created thoracic duct-to-azygous vein lymphovenous anastomosis (TDA-LVA) to provide lymphatic decompression in critically ill neonates and infants with thoracic duct obstruction.</div></div><div><h3>Methods</h3><div>All children who underwent TDA-LVA creation at the Children’s Hospital of Philadelphia between December 2019 and January 2024 were retrospectively reviewed. Preoperative and postoperative clinical characteristics were compared among all patients. Primary end points of analysis included survival to discharge and at last follow-up.</div></div><div><h3>Results</h3><div>Eight children (median weight, 4.5 kg; interquartile range [IQR], 3.5-5.0 kg) underwent successful TDA-LVA creation. All procedures were tolerated very well. One patient (1 of 8 [12.5%]) required chest washout on postoperative day (POD) 7, and 1 TDA-LVA was unsuccessfully revised on POD 21. The median hospital length of stay after TDA-LVA creation was 138 days (IQR, 64-241 days). Overall, 6 of 8 patients (75.0%) survived to hospital discharge, all of which (6 of 6 [100.0%]) remained alive at a median follow-up of 165 days (IQR, 18-521 days) after discharge. Postoperative TDA-LVA patency was confirmed with conventional lymphangiography in 5 of 8 patients (62.5%), and up to POD 70.</div></div><div><h3>Conclusions</h3><div>A TDA-LVA can restore lymphatic fluid drainage into the systemic venous circulation and remain patent for >2 months in carefully selected patients with thoracic duct obstruction. Further investigations are needed to determine the long-term durability and potential impact on overall quality of life and survival in children with complex lymphatic disorders.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"4 1","pages":"Pages 153-158"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147414895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standardization for Minimally Invasive Combined Aortic and Mitral Valve Surgery via a Right Minithoracotomy 经右小开胸微创主动脉二尖瓣联合手术的标准化

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-07-31 DOI: 10.1016/j.atssr.2025.07.011

Masataka Yamazaki MD, PhD , Tatsuo Takahashi MD , Yorihiko Matsumoto MD, PhD , Hirofumi Haida MD , Naritaka Kimura MD, PhD , Kenichi Hashizume MD, PhD , Tsutomu Ito MD, PhD , Hideyuki Shimizu MD, PhD

Surgeons have been reluctant to adopt minimally invasive combined aortic and mitral valve surgery through a minithoracotomy because of its complexity and prolonged cardiopulmonary bypass and aortic cross-clamping times. Our technique was designed to provide a close and frontal surgical visual field without the need for long-shafted specialized surgical instruments, thereby allowing a standardized and well-visualized surgical visual field in many cases. Here we describe the implementation of our minimally invasive combined aortic and mitral valve surgical procedure through a right minithoracotomy facilitated by the superior septal approach for mitral valve access.

外科医生一直不愿意采用微创主动脉二尖瓣联合手术通过小开胸，因为它的复杂性和延长的体外循环和主动脉交叉夹夹时间。我们的技术旨在提供近距离和正面的手术视野，而不需要长轴的专业手术器械，从而在许多情况下允许标准化和良好的手术视野。在这里，我们描述了我们的微创主动脉瓣和二尖瓣联合手术的实施，通过右小开胸，通过上间隔入路进入二尖瓣。

引用次数: 0

The Current State and Challenges in Cardiothoracic Surgery in Latin America 拉丁美洲心胸外科的现状和挑战

Annals of thoracic surgery short reports

Pub Date : 2026-03-01 Epub Date: 2025-10-06 DOI: 10.1016/j.atssr.2025.09.008

W. Samir Cubas MD, MSc , Dominique Vervoort MD, MPH , Víctor Dayán MD, PhD , Josias Ríos-Ortega MD , Lorena Montes MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annals of thoracic surgery short reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀